Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 3 May 2002:
Vol. 296. no. 5569, pp. 820 - 821
DOI: 10.1126/science.296.5569.820
Prev | Table of Contents | Next

News of the Week

PEDIATRIC DRUG TRIALS:
Challenge to FDA's Authority May End Up Giving It More

Eliot Marshall

In a recent 4-week period, the U.S. government reversed course twice on whether drugmakers should be compelled to test their products on children. The muddle ended 19 April when the Bush Administration came out in favor of retaining a 3-year-old rule that gives the Food and Drug Administration (FDA) power to demand that companies conduct targeted studies to learn about side effects and set proper doses for children. Several senators responded this week by proposing to give FDA permanent authority to order such clinical trials.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Medical Information Systems in Pediatrics.
C. U. Lehmann (2003)
Pediatrics 111, 679
   Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)